In this situation, differential EBV latency‐II‐specific effector CD8+ T cell immune surveillance might contribute to the pathogenesis of EBV+cHL by attenuating immune‐mediated destruction of premalignant B cells. This evidence concerns the gene CD8A and classic Hodgkin lymphoma.